Clinical, Cosmetic and Investigational Dermatology (Sep 2014)

Ustekinumab for the treatment of psoriatic arthritis: an update

  • Davari P,
  • Leo MS,
  • Kamangar F,
  • Fazel N

Journal volume & issue
Vol. 2014, no. default
pp. 243 – 249

Abstract

Read online

Parastoo Davari, Michael S Leo, Faranak Kamangar, Nasim Fazel Department of Dermatology, University of California, Davis, CA, USA Abstract: Psoriatic arthritis occurs in 30% of psoriasis patients, and the treatment can be challenging in some patients. Recently, the US Food and Drug Administration approved ustekinumab, a fully human monoclonal antibody, for the management of psoriatic arthritis. In this article, we review large-scale randomized clinical trials addressing the efficacy and safety profile of ustekinumab for the treatment of psoriatic arthritis. Keywords: psoriatic arthritis, psoriasis, ustekinumab